Peptide receptor radionuclide therapy in malignant insulinoma
Endocrine-Related Cancer · 01.06.2025 · 32 (6)
DOI: 10.1530/erc-25-0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 27.05.2025. Verfasst von David A Pattison und 13 weiteren Autor:innen. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms, Octreotide, Receptors, Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
The management of malignant insulinoma (MI) presents dual management challenges of hypoglycaemia and tumour control. This study aims to analyse long-term outcomes of PRRT for the treatment of MI. We retrospectively reviewed consecutive patients with MI treated with [177Lu]Lu-DOTATATE (LuTATE) at two Australian NET centres between 2004 and 2022. Follow-up for hypoglycaemia, molecular imaging, radiologic and biochemical responses, treatment-related side-effects, progression-free and overall survival were assessed. Of 15 patients (seven female; median age 60, range 26–82) treated for intractable hypoglycaemia, WHO grade (G) was known in 12 patients (three G1, six G2 and three G3). PRRT was administered in a median of seven cycles (range 1–15), with a median cumulative activity of 42 GBq (range 4–117 GBq) and radiosensitizing chemotherapy in 9/15 (60%) patients. Resolution of hypoglycaemia was observed in 14/15 (93%) patients after a median of 2.5 months (range 0.2–23.5), but recurred in 7/14 cases after a median of 17.7 months (range 7.6–48.3). Patients with recurrent hypoglycaemia had a longer time to hypoglycaemia resolution (median 3.0 vs 0.5 months), were more likely G3 (57 vs 0%) and experienced higher mortality (86 vs 29%). In all seven cases, PRRT re-treatment was successful. The mean duration of hypoglycaemia remission was 23.8 months (range 9.2–101). The median progression-free and overall survival was 17.9 months (95% CI, 8.5–43.2) and 50.1 months (95% CI, 23.0-ND), respectively. Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients. PRRT provides durable hypoglycaemic and oncologic disease control of MI with manageable toxicity including hypoglycaemia flare requiring multidisciplinary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: David A Pattison, Grace Kong, Timothy Akhurst, Matthew Burge, Cherie Chiang, Michael S Hofman, Te-Jui Hung, Amanda Love, Michael Michael, Satomi Okano, Aravind S Ravi Kumar, Nirupa Sachithanandan, David Wyld, Rodney J Hicks
Zitieren
APA
Pattison, D. A., Kong, G., Akhurst, T., Burge, M., Chiang, C., Hofman, M. S., Hung, T. J., Love, A., Michael, M., Okano, S., Ravi Kumar, A. S., Sachithanandan, N., Wyld, D., & Hicks, R. J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32(6). https://doi.org/10.1530/erc-25-0018
Vancouver
Pattison DA, Kong G, Akhurst T, Burge M, Chiang C, Hofman MS, et al. Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer. 2025;32(6). doi:10.1530/erc-25-0018
BibTeX
@article{Pattison2025,
author = {Pattison, David A and Kong, Grace and Akhurst, Timothy and Burge, Matthew and Chiang, Cherie and Hofman, Michael S and Hung, Te-Jui and Love, Amanda and Michael, Michael and Okano, Satomi and Ravi Kumar, Aravind S and Sachithanandan, Nirupa and Wyld, David and Hicks, Rodney J},
title = {Peptide receptor radionuclide therapy in malignant insulinoma},
journal = {Endocrine-Related Cancer},
year = {2025},
volume = {32},
number = {6},
doi = {10.1530/erc-25-0018}
}
EUVIMED